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Effect of hepatic steatosis on virological response to nucleos(t)ide
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Aim: To evaluate the impact of hepatic steatosis on the outcome of treatment in patients with chronic hepatitis B infection treated with
oral antiviral therapy.
Materials and methods: The study was designed in Erciyes University Medical Faculty Department of Gastroenterology. Patients who
received oral antiviral therapy because of chronic hepatitis B were included in the study. Liver biopsy specimens were re-evaluated and
classified according to Brunt’s steatosis classification. Virological response to oral antiviral therapy was compared between patients with
and without steatosis.
Results: One hundred and nineteen patients were included in the study, of which 36.1% had hepatic steatosis. Virological response
rates were 81% and 85.5% in patients with steatosis and without steatosis, respectively. There was no statistically significant difference in
virological response rate between patients with and without steatosis (p: 0.78). Median hepatic fibrosis values were 3 and 2 in patients
with steatosis and without steatosis respectively (p: 0.01).
Conclusion: Many studies have researched the prevalence and effect of steatosis on the liver in chronic hepatitis B. Although steatosis
does not affect the outcome of treatment, it is not a rare condition in chronic hepatitis B.
Key words: Hepatic steatosis, hepatitis B, viral response, antiviral therapy, nucleos(t)ide analogs, liver fibrosis

1. Introduction
Lipid accumulation in the liver, so-called hepatic steatosis
or nonalcoholic fatty liver disease (NAFLD), is a common
condition frequently found in subjects who are not
affected by any other liver disease and who do not drink
alcohol; it affects 10%–24% of the population (1). Hepatic
steatosis prevalence has been estimated by magnetic
resonance studies to be 35% in the general population
and to be 75% in obese persons, and these figures seem to
be continually increasing (2–4). In fact, in only 2% of the
general population does hepatic steatosis constitute a real
hepatic disease: nonalcoholic steatohepatitis (NASH) with
deranged aminotransferases and fibrosis.
Hepatitis B virus (HBV) infection continues to be
a major health problem worldwide. It is estimated that
there are over 400 million chronic carriers of HBV (5).
One study reported that the seroprevalence of hepatitis
B is 2.2% in Turkey (6). There is a high prevalence
* Correspondence: drkaraman@hotmail.com
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of hepatitis B in blood donors in some countries (7).
Chronically infected individuals have a higher risk of
death from cirrhosis and liver cancer. It is well known
that hepatic steatosis is reported to share common
histological features with chronic hepatitis C (CHC), and
is associated with metabolic and viral factors. Hepatic
steatosis may affect the severity of fibrosis in CHC (8). The
prevalence and clinical significance of steatosis in patients
with chronic hepatitis B (CHB) are poorly understood.
We suggest that there is a relationship between response
to CHB treatment and hepatic steatosis. Only a small
number of studies on this subject have been published
and some of these reported the prevalence of steatosis
in CHB (9,10). The presence of steatosis correlates with
body mass index (BMI), waist circumference, high blood
pressure, and dyslipidemia, but not with viral genotype
or viral load. Moreover, steatosis does not correlate with
fibrosis (8).
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Nucleos(t)ide analogs (NUCs) are an approved
treatment for CHB. HBeAg, ALT, and HBV DNA
measurements could be of significant help in the selection
of hepatitis B patients who would benefit from antiviral
treatment. HbeAg seroconversion and undetectable
HBV DNA level are associated with increased survival in
patients with CHB (11). However, the impact of hepatic
steatosis on the response rate to antiviral treatment,
especially with NUCs, has not been studied in CHB.
The aim of this retrospective study was to determine the
prevalence of hepatic steatosis in CHB and the impact of
hepatic steatosis on the outcome of treatment in patients
with CHB treated with NUCs.
2. Materials and methods
This study was approved by the Ethics Committee of Erciyes
University Faculty of Medicine. The patients who were
treated and monitored for CHB infection at the Department
of Gastroenterology at Erciyes University from 2005 to 2010
were reached via patient follow-up cards and computerbased patient records. Patients who had already received
NUCs or had previously been treated with these drugs for at
least 48 weeks for CHB infection were included in the study.
Patients who had concurrent CHC and chronic hepatitis
D infection, any chronic liver disorders, chronic alcohol
dependence, had previously been treated with interferon,
and those with cirrhosis were excluded. Diagnosis of CHB
infection was made from a liver biopsy showing findings
for CHB; a biopsy was performed after the determination
of HBsAg, detection of HBV DNA, or elevated ALT levels
measured in 2 separate samples taken at least 6 months
apart. The demographical data of the patients were recorded
and used for statistical analyses.
2.1. Histological evaluation
The pathology samples of patients were reviewed
retrospectively and re-assessed by an experienced
pathologist in the pathology laboratory. The slides were
stained with hematoxylin–eosin, silver, and trichrome
stains and were evaluated under a light microscope
(Olympus, BX51, Japan) according to the modified Ishak
system (12). Hepatic steatosis was scored according to
Brunt’s classification (13).
2.2. Treatment protocols and evaluation of the response
to treatment
Virological response to NUCs was defined as undetectable
HBV DNA by real-time PCR assay within 48 weeks of
therapy. The rate of viral response to NUCs was assessed
independently from the steatosis. The liver biopsies of
patients who had received NUCs (lamivudine, entecavir,
or tenofovir) for at least 48 weeks were grouped according
to Brunt’s classification as grade 0, 1, 2, or 3 steatosis. They
were also evaluated in 2 groups as those with and without
steatosis.

2.3. Statistical analysis
Data were initially assessed for normality and logtransformed where appropriate. Baseline descriptive data
were expressed as means and standard deviations for
continuous variables and as frequencies and percentages
for categorical variables. A Shapiro–Wilk test was used
to assess the normal distribution of data. The analysis of
qualitative variables was assessed using a chi-square test.
To compare numerical values Student’s t-test was used if
the data had a normal distribution while a Mann–Whitney
U test was used if the data did not. For all comparisons,
statistical significance was determined at the 0.05 level.
3. Results
One hundred and nineteen patients were included in the
study, of whom 76 (63.8%) were male and 43 (36.2%)
female. The mean age, basal ALT levels, basal HBV-DNA
levels, HAI scores, fibrosis scores, BMI, total cholesterol,
and fasting triglyceride levels of groups with and without
steatosis are shown in Table 1. There were statistically
significant differences in BMI, total cholesterol, and fasting
triglyceride levels between the groups (Table 1). Apart
from hepatic steatosis, 100 (84.1%) of the 119 patients
had a virological response at week 48, whilst 19 patients
(15.9%) had no or a partial virological response. When
the rates of treatment responses were compared according
to sex and age, no statistically significant difference was
found (Table 2).
Seventy-eight (63.9%) of the 119 patients had no
steatosis, 36 (30.3%) had grade 1 steatosis, and 7 (5.9%)
had grade 2 steatosis. No statistically significant difference
in virological response was found between the groups
(Table 3).
4. Discussion
Hepatic steatosis may occur as a common histopathological
sign of several liver disorders unrelated to each other in
terms of causes, pathogenesis, and clinical courses. The
clinical course may be ingenuous or may result in cirrhosis,
leading to severe necroinflammation and fibrosis, causing
significant risks of liver-related morbidity and mortality.
Hepatic steatosis is a metabolic disease that makes the
liver more vulnerable to harmful agents and leads to
accumulation of fatty tissue within the liver. Therefore, it
is expected that patients with hepatic steatosis will have
a poorer response to antiviral treatment. It is known
that hepatic steatosis has a negative effect on treatment
responses in CHC infection. It was reported that HCV
core protein played an important role in the development
of steatosis in CHC infection. It was proposed that HCV
caused viral steatosis in addition to metabolic steatosis
(14). That argument may explain why steatosis is more
common in CHC when compared with CHB.
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Table 1. Comparisons of patients with and without steatosis.
Parameter

Whole group
(n = 119)

With steatosis
(n = 43 36.1%)

Without steatosis
(n = 76 63.9%)

P

Age (years)

41.3 ± 13.7

43.8 ± 11.7

40.03 ± 13.8

>0.05

Age of males

42 ± 13.9

41.9 ± 14.04

42.2 ± 13.89

0.9

40.1 ± 13.57

43.7 ± 13.19

35.9 ± 13.03

0.029

Median value of basal ALT (IU/L)

85

74.5

93.0

0.17

Median value of HAI

5

5

4

0.18

Median value of fibrosis

3

3

2

0.01

1.2 × 107

9.9 × 106

1.3 × 107

0.451

26 ± 4

29 ± 5

25 ± 4

0.001

Total cholesterol (mg/dL)

209 ± 72

260 ± 62

180 ± 60

0.001

Triglyceride (mg/dL)

202 ± 55

240 ± 52

182 ± 58

0.001

Age of females

Basal HBV-DNA (IU/mL)
BMI (kg/m2)

Table 2. Comparison of patients according to virological response.
Patients having virological
response to treatment
n (%)

Patients not having virological
response to treatment
n (%)

Men

65 (86)

11 (14)

Women

35 (82)

8 (18)

General

100 (84.1)

19 (15.9)

0.076

Age

42.4 ± 13

36.7 ± 16.2

0.16

With steatosis

35/43 (81)

8/43 (19)

65/76 (85.5)

11/76 (14.5)

Parameter

Without steatosis

0.63

0.78

Table 3. Distribution of hepatic steatosis and virological response.
Grading of steatosis

Number (%)

Virological response %

None

76 (63.9)

85.5

Grade 1

36 (30.3)

81.8

Grade 2

7 (5.9)

83.3

Grade 3

0

-

119

84.8

Total

No statistically significant difference between groups.
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There is an insufficient number of studies relevant to
the natural course and treatment response rates of patients
with CHB infection and hepatic steatosis. The prevalence
of hepatic steatosis was 42.4% and hepatic steatosis was
only correlated with serum triglyceride level in patients
with CHB in a study from Iran (15). In contrast, Shi et al.
reported that steatosis was independent of factors such as
BMI, serum triglyceride and apoprotein levels, uric acid,
and fasting plasma glucose in patients with CHB (16).
The prevalence of hepatic steatosis was 33.4% in a study
reported by Mi et al. (17). In that study, BMI, fasting blood
glucose, serum triglyceride, and the total cholesterol levels
of patients with steatosis were significantly higher than
those of patients without steatosis (17). Shi et al. evaluated
562 patients with CHB infection and found that the rate
of hepatic steatosis was 18.15%. The results obtained from
patients with steatosis were similar to the data of the studies
mentioned above (18). In a study conducted in Tunisia,
Elloumi et al. reported a hepatic steatosis rate of 34.1% in
patients with CHB and the authors reported that only BMI
and serum cholesterol levels were influential factors in the
development of hepatic steatosis in the patients with CHB
(19). As seen in these studies, the rates of steatosis varied
widely. This variability may result from different ethnicity,
certain metabolic properties of the population included
in the study, and even from individual differences during
histopathological evaluations.
When the literature was reviewed, it was seen that the
data regarding the effect of hepatic steatosis on treatment
were rather limited in CHB. Cindoruk et al. conducted
a study to ascertain if hepatic steatosis affects response
to treatment in patients receiving interferon for CHB
infection. In that study, the prevalence of hepatic steatosis
was 34.2% and it was concluded that hepatic steatosis did
not affect treatment response (20). In our study, although
hepatic steatosis was observed at a rate of 36.1% in patients
with CHB, it did not impact virological response.
The association between steatosis and fibrosis is a
common observation in NASH. Because of this fact

we did not include patients with NASH in the study.
While Peng et al. reported that steatosis was not related to
fibrosis (9), we found a statistically significant correlation
between steatosis and hepatic fibrosis; the more steatosis
increases, the more fibrosis develops. The observation that
fibrosis is significantly higher in patients with steatosis
is not new, and, in any case, the relationships between
steatosis and fibrosis have been evaluated in different
studies (20,21). Considering that the main cause of
morbidity and mortality due to hepatitis B infection is
related to the development of hepatic fibrosis, this is an
important finding. It is well known that hepatic steatosis
resulting from any cause leads to oxidative stress and
mitochondrial dysfunction and consequent inflammatory
changes and fibrosis (22,23). In CHC infection, increased
fibrosis due to steatosis is related to many pathways such as
oxidative stress, increased vulnerability to apoptosis, and
impaired response to cellular damage. Similar pathways
may also take place in CHB infection with hepatic steatosis;
further studies on this subject are needed.
Although the rates of VR in patients with hepatic
steatosis treated with NUCs were lower in comparison
with those without hepatic steatosis who received the same
treatment, there was no significant difference between the
groups. This situation may be related to the low severity of
the steatosis present in the patients with steatosis in this
study.
Our study had certain limitations (lack of some
parameters such as insulin resistance) since it was a
retrospective study. Another limitation was that genotypes
were not known; however, most patients with CHB in
Turkey have genotype D. Considering this information
and studies reporting that the outcomes of treatments
with oral antiviral drugs are independent of the HBV
genotype, it is thought that these limitations may not have
significantly affected the results of the study (23).
In conclusion, hepatic steatosis is not rare in patients
with CHB but it does not affect the virological response to
oral antiviral treatment in these patients.
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